Press Releases Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-12-03 pm EST			5-day change	1st Jan Change
58.69 ^USD	-2.09%		-0.09%	+14.38%

Dec. 03	Bristol-Myers Squibb Company Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:00 AM
Dec. 03	AI Proteins, Inc. Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued Up to $400 Million	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference	Nov. 26	BU
Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms	Nov. 20	AQ
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms	Nov. 19	BU
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors	Nov. 18	AQ
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer	Nov. 18	AQ
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer	Nov. 15	BU
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors	Nov. 15	BU
Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024	Nov. 11	BU
Bristol Myers Squibb : Statement of Changes in Beneficial Ownership - Form 4	Nov. 05	PU
Bristol Myers Squibb : Statement of Changes in Beneficial Ownership - Form 4	Nov. 05	PU
Bristol Myers Squibb : Statement of Changes in Beneficial Ownership - Form 4	Nov. 05	PU
Bristol Myers Squibb : Statement of Changes in Beneficial Ownership - Form 4	Nov. 05	PU
Bristol Myers Squibb : Statement of Changes in Beneficial Ownership - Form 4	Nov. 05	PU
Bristol Myers Squibb to Participate in Upcoming Investor Conferences	Nov. 05	BU
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024	Oct. 31	BU
Bristol Myers Squibb : Reports Third Quarter Financial Results for 2024 Form 8 K	Oct. 31	PU
Bristol Myers Squibb : Q3 2024 Results Presentation (with Appendix)	Oct. 31	PU
Bristol Myers: Q3 Earnings Snapshot	Oct. 31	AQ
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024	Oct. 31	BU
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024	Oct. 28	BU
Dismissal Of $6.4 Billion Lawsuit Serves As A Reminder To Debt Security Holders To Obtain Depositary Proxies Before Pursuing Litigation	Oct. 17	AQ
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)	Oct. 03	BU
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting	Sep. 30	AQ
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults	Sep. 30	AQ
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting	Sep. 27	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST